About Ovarian Cancer Each year, there are approximately 21,300 new cases of ovarian cancer diagnosed in the US and more than 14,200 women die from the disease. 3 Once the cancer has been treated with several lines of combination regimens, patients may be treated with single-agent therapy, which typically have response rates around 15-20%. 4 About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead wholly owned product candidate, mirvetuximab soravtansine, is a potential treatment for FRα-positive ovarian cancers and other solid tumors. Major healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies; Roche's marketed product, Kadcyla ®, utilizes ImmunoGen's ADC technology.